Mizolastine

DB12523

small molecule approved investigational

Deskripsi

Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).

Struktur Molekul 2D

Berat 432.503
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

402 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Mizolastine.
Benzylpenicilloyl polylysine Mizolastine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Mizolastine.
Amphetamine Amphetamine may decrease the sedative activities of Mizolastine.
Phentermine Phentermine may decrease the sedative activities of Mizolastine.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Mizolastine.
Benzphetamine Benzphetamine may decrease the sedative activities of Mizolastine.
Diethylpropion Diethylpropion may decrease the sedative activities of Mizolastine.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Mizolastine.
Mephentermine Mephentermine may decrease the sedative activities of Mizolastine.
MMDA MMDA may decrease the sedative activities of Mizolastine.
Midomafetamine Midomafetamine may decrease the sedative activities of Mizolastine.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Mizolastine.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Mizolastine.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Mizolastine.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Mizolastine.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Mizolastine.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Mizolastine.
Metamfetamine Metamfetamine may decrease the sedative activities of Mizolastine.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Mizolastine.
Ritobegron Ritobegron may decrease the sedative activities of Mizolastine.
Mephedrone Mephedrone may decrease the sedative activities of Mizolastine.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Mizolastine.
Gepefrine Gepefrine may decrease the sedative activities of Mizolastine.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Mizolastine.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Mizolastine.
Dofetilide The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Dofetilide.
Citalopram The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Valproic acid.
Terfenadine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Terfenadine.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Grepafloxacin.
Quinine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Quinine.
Toremifene The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Toremifene.
Cisapride The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Cisapride.
Imatinib The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Imatinib.
Thioridazine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Thioridazine.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Mifepristone.
Cocaine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Cocaine.
Quinidine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Quinidine.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Arsenic trioxide.
Escitalopram The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Escitalopram.
Domperidone The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Sparfloxacin.
Halofantrine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Halofantrine.
Bepridil The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Tetrabenazine.
Dronedarone The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Dronedarone.
Nilotinib The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Nilotinib.
Iloperidone The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Iloperidone.
Vandetanib The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Vandetanib.
Romidepsin The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Romidepsin.
Asenapine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Lumefantrine.
Vemurafenib The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Vemurafenib.
Eliglustat The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Eliglustat.
Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Mizolastine.
Glasdegib The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Terodiline.
Amiodarone The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Amiodarone.
Sotalol The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Sotalol.
Erlotinib The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Erlotinib.
Astemizole The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Astemizole.
Procainamide The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Procainamide.
Pimozide The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Pimozide.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Mizolastine.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Mizolastine.
Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Mizolastine.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Mizolastine.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mizolastine.
Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Mizolastine.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Mizolastine.
Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Mizolastine.
Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Mizolastine.
Clozapine The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Mizolastine.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Mizolastine.
Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Mizolastine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Mizolastine.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Mizolastine.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Mizolastine.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Mizolastine.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Mizolastine.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Mizolastine.
Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Mizolastine.
Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Mizolastine.
Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Mizolastine.
Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Mizolastine.
Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Mizolastine.

Target Protein

Histamine H1 receptor HRH1

Referensi & Sumber

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Mizollen

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul